Xenon Pharmaceuticals Inc.

NASDAQ:XENE

38.19 (USD) • At close September 8, 2025
Bedrijfsnaam Xenon Pharmaceuticals Inc.
Symbool XENE
Munteenheid USD
Prijs 38.19
Beurswaarde 2,944,670,502
Dividendpercentage 0%
52-weken bereik 26.74 - 46
Industrie Biotechnology
Sector Healthcare
CEO Mr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA
Website https://www.xenon-pharma.com

An error occurred while fetching data.

Over Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium

Vergelijkbare Aandelen

Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc.

TVTX

21.2 USD

Krystal Biotech, Inc. logo

Krystal Biotech, Inc.

KRYS

145.2 USD

ImmunityBio, Inc. logo

ImmunityBio, Inc.

IBRX

2.41 USD

Establishment Labs Holdings Inc. logo

Establishment Labs Holdings Inc.

ESTA

38.245 USD

Addus HomeCare Corporation logo

Addus HomeCare Corporation

ADUS

114.36 USD

Ligand Pharmaceuticals Incorporated logo

Ligand Pharmaceuticals Incorporated

LGND

165.86 USD

Dynavax Technologies Corporation logo

Dynavax Technologies Corporation

DVAX

9.7 USD

Supernus Pharmaceuticals, Inc. logo

Supernus Pharmaceuticals, Inc.

SUPN

45.82 USD

ModivCare Inc. logo

ModivCare Inc.

MODV

0.432 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)